Cite
HARVARD Citation
Gaztanaga, J. et al. (2021). A pilot open-label study of aldose reductase inhibition with AT-001 (caficrestat) in patients hospitalized for COVID-19 infection: Results from a registry-based matched-control analysis. Diabetes & metabolic syndrome. 15 (6), p. . [Online].